Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

A. Schram, M. Borad, V. Sahai, S. Kamath, R. Kim, C. Y.A. Liao, D. Y. Oh, M. Ponz-Sarvisé, J. Yachnin, S. A. Shell, P. Cassier, E. Dotan, V. Florou, V. Moreno, J. O. Park, D. Tai, O. Schmidt-Kittler, C. Ferté, L. Goyal, V. Subbiah

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)S116
JournalEuropean Journal of Cancer
StatePublished - Oct 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this